85%Confidence
0Views
FDASource
2026-03-06Date
Summary
Amerisource faces packaging defects for oxycodone tablets, creating potential diversion risks and patient safety concerns for controlled substances. This could trigger increased DEA scrutiny and supply chain disruptions for pain management medications.
Actionable: Immediately verify packaging integrity for oxycodone inventory and implement additional quality checks.
AI Confidence: 85%
Data Points
firmAmerisource Health Services LLC
classificationClass II
statusOngoing
distributionNationwide in the USA
productOxycodone Hydrochloride Tablets, USP (CII), 5 mg, 100-Count (10 x 10) blister cards per carton, Rx Only, The drug product contained in this package
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now